PMID- 19522540
OWN - NLM
STAT- MEDLINE
DCOM- 20100330
LR  - 20231213
IS  - 1535-3907 (Electronic)
IS  - 1535-3893 (Linking)
VI  - 9
IP  - 1
DP  - 2010 Jan
TI  - Circulating Lamin B1 (LMNB1) biomarker detects early stages of liver cancer in 
      patients.
PG  - 70-8
LID - 10.1021/pr9002118 [doi]
AB  - Hepatocellular carcinoma (HCC) is a major liver malignancy possessing a high 
      mortality rate and is particularly prevalent in China and Asia. While surgery is 
      the most effective treatment for liver tumor, about 80% of HCC patients are 
      inoperable at presentation and die early due to late diagnosis. For early cancer 
      detection, we employed a proteomic expression profiling approach to identify 
      biomarkers for early stages of HCC and subsequently assessed the clinical 
      feasibility of a novel marker in plasma. Frozen liver tissues from a 
      retrospective cohort of 75 liver patients (39 HCCs, 20 cirrhosis, and 16 
      nondiseased subjects) were subjected to proteome-wide expression profiling by 
      2-DE. MALDI-TOF/TOF was used to identify differentially expressed proteins, which 
      were further confirmed by immunoblotting, qPCR, and immunohistochemistry. 
      Conventional RT-PCR was employed to further analyze the abundance of selected 
      biomarker at mRNA level in a separate cohort of 63 plasma samples (35 HCCs, 16 
      liver cirrhosis, 12 healthy individuals). We successfully identified lamin B1 
      (LMNB1) that was significantly upregulated in HCC tumors and present in patients' 
      plasma. LMNB1 functions in nuclear envelope lamina and possesses a 
      transcriptional coregulatory activity having an important role in DNA 
      replication, cellular aging, and stress responses. Clinically, the expression 
      level of lamin B1 correlated positively with tumor stages, tumor sizes, and 
      number of nodules. Our findings further showed elevation of circulating LMNB1 
      marker in plasma could detect early stages of HCC patients, with 76% sensitivity 
      and 82% specificity. In conclusion, lamin B1 is a clinically useful biomarker for 
      early stages of HCC in tumor tissues and plasma, and warrants further clinical 
      investigation.
FAU - Sun, Stella
AU  - Sun S
AD  - Department of Surgery, LKS Faculty of Medicine, The University of Hong Kong, 
      Pokfulam, Hong Kong.
FAU - Xu, Michelle Z
AU  - Xu MZ
FAU - Poon, Ronnie T
AU  - Poon RT
FAU - Day, Philip J
AU  - Day PJ
FAU - Luk, John M
AU  - Luk JM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Proteome Res
JT  - Journal of proteome research
JID - 101128775
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Lamin Type B)
RN  - 0 (RNA, Messenger)
SB  - IM
MH  - Adult
MH  - Analysis of Variance
MH  - Biomarkers, Tumor/*blood/genetics
MH  - Female
MH  - Humans
MH  - Lamin Type B/*blood/genetics
MH  - Liver Neoplasms/*blood/genetics
MH  - Male
MH  - Middle Aged
MH  - RNA, Messenger/blood/genetics
MH  - Reproducibility of Results
MH  - Sensitivity and Specificity
EDAT- 2009/06/16 09:00
MHDA- 2010/03/31 06:00
CRDT- 2009/06/16 09:00
PHST- 2009/06/16 09:00 [entrez]
PHST- 2009/06/16 09:00 [pubmed]
PHST- 2010/03/31 06:00 [medline]
AID - 10.1021/pr9002118 [doi]
PST - ppublish
SO  - J Proteome Res. 2010 Jan;9(1):70-8. doi: 10.1021/pr9002118.